Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $139,304.96 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 4,096 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $34.01, for a total transaction of $139,304.96. Following the transaction, the chief financial officer directly owned 16,908 shares in the company, valued at approximately $575,041.08. This trade represents a 19.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Yajing Chen also recently made the following trade(s):

• On Thursday, June 26th, Yajing Chen sold 2,675 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total transaction of $96,647.75.
• On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00.

Zai Lab Stock Performance

NASDAQ ZLAB opened at $35.63 on Thursday. The firm’s 50 day moving average price is $36.76 and its 200-day moving average price is $33.38. Zai Lab Limited Unsponsored ADR has a 52-week low of $16.03 and a 52-week high of $44.34. The company has a market cap of $3.96 billion, a PE ratio of -17.47 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The firm had revenue of $109.98 million for the quarter, compared to the consensus estimate of $125.66 million. On average, analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Zai Lab during the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Zai Lab during the first quarter worth $75,000. Barclays PLC lifted its stake in shares of Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after buying an additional 2,856 shares during the period. Advisors Preferred LLC acquired a new stake in shares of Zai Lab during the first quarter worth $110,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Zai Lab during the first quarter worth $203,000. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on ZLAB. Citigroup reaffirmed a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Zai Lab in a research report on Monday. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the stock an “outperform” rating in a research report on Monday, June 30th. Finally, Wall Street Zen downgraded shares of Zai Lab from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.22.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.